Long-term follow-up of patients treated with ICD: Benefit in patients with preserved left ventricular function

Scandinavian Cardiovascular Journal

Volumn 42, Issue 2, 2008, Pages 125-129

  Rönn, Folke ^a   Kesek, Milos ^a   Höglund, Niklas ^a   Jensen, Steen M ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; SOTALOL; WARFARIN;

ADOLESCENT; ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CAUSE OF DEATH; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEFIBRILLATOR; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART DEATH; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SCHOOL CHILD; SINUS TACHYCARDIA; TREATMENT FAILURE;

EID: 41549104255     PISSN: 14017431     EISSN: 16512006     Source Type: Journal    
DOI: 10.1080/14017430701762719     Document Type: Article

References (20)

1. Hlatky MA, Mark DB. The high cost of implantable defibrillators. Eur Heart J. 2007;28:388-91.
2. Lynd LD, O'Brien BJ. Cost-effectiveness of the implantable cardioverter defibrillator: A review of current evidence. J Cardiovasc Electrophysiol. 2003;14:S99-S103.
3. Kuck KH, Nisam S. ICD therapy: 'The sickest benefit the most . . .': What about the less sick? Europace. 2006;8: 508-11.
4. Tandri H, Griffith LS, Tang T, Nasir K, Zardkoohi O, Reddy CV, et al. Clinical course and long-term follow-up of patients receiving implantable cardioverter-defibrillators Heart Rhythm. 2006;3:762-8.
5. Dehghani MR, Arya A, Haghjoo M, Emkanjoo Z, Alasti M, Kazemi B, et al. Predictors of appropriate ICD therapy in patients with implantable cardioverter-defibrillator. Indian Pacing Electrophysiol J. 2006;6:17-24.
6. Klein G, Lissel C, Fuchs AC, Gardiwal A, Oswald H, Desousa M, et al. Predictors of VT/VF-occurrence in ICD patients: Results from the PROFIT-Study. Europace. 2006;8:618-24.
7. Exner DV, Sheldon RS, Pinski SL, Kron J, Hallstrom A. Do baseline characteristics accurately discriminate between patients likely versus unlikely to benefit from implantable defibrillator therapy? Evaluation of the Canadian implantable defibrillator study implantable cardioverter defibrillatory efficacy score in the antiarrhythmics versus implantable defibrillators trial. Am Heart J. 2001;141:99-104.
8. Domanski MJ, Sakseena S, Epstein AE, Hallstrom AP, Brodsky MA, Kim S, et al. Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias. AVID Investigators. Antiarrhythmics Versus Implantable Defibrillators. J Am Coll Cardiol. 1999;34:1090-5.
9. Oseroff O, Retyk E, Bochoeyer A. Subanalyses of secondary prevention implantable cardioverter-defibrillator trials: Antiarrhythmics versus implantable defibrillators (AVID), Canadian Implantable Defibrillator Study (CIDS), and Cardiac Arrest Study Hamburg (CASH). Curr Opin Cardiol. 2004;19:26-30.
10. Lee DS, Green LD, Liu PP, Dorian P, Newman DM, Grant FC, et al. Effectiveness of implantable defibrillators for preventing arrhythmic events and death: A meta-analysis. J Am Coll Cardiol. 2003;41:1573-82.
11. Alter P, Waldhans S, Plachta E, Moosdorf R, Grimm W. Complications of implantable cardioverter defibrillator therapy in 440 consecutive patients. Pacing Clin Electrophysiol. 2005;28:926-32.
12. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J. 2000;21:2071-8.
13. Chen L, Hay JW. Cost-effectiveness of primary implanted cardioverter defibrillator for sudden death prevention in congestive heart failure. Cardiovasc Drugs Ther. 2004;18:161-70.
14. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-37.
15. Gradaus R, Block M, Brachmann J, Breithardt G, Huber HG, Jung W, et al. Mortality, morbidity, and complications in 3344 patients with implantable cardioverter defibrillators: Results fron the German ICD Registry EURID. Pacing Clin Electrophysiol. 2003;26:1511-8.
16. Kuhlkamp V, Wilkoff BL, Brown AB, Volosin KJ, Hugl BJ, Stafford W, et al. Experience with a dual chamber implantable defibrillator. Pacing Clin Electrophysiol. 2002;25:1041-8.
17. Mewis C, Kuhlkamp V, Dornberger V, Mermi J, Seipel L. High incidence of isolator fractures in transvenous implantation of cardioverter defibrillators. Z Kardiol. 1997;86:85-94.
18. Dorwarth U, Frey B, Dugas M, Matis T, Fiek M, Schmoeckel M, et al. Transvenous defibrillation leads: High incidence of failure during long-term follow-up. J Cardiovasc Electrophysiol. 2003;14:38-43.
19. Rosenqvist M, Beyer T, Block M, den Dulk K, Minten J, Lindemans F. Adverse events with transvenous implantable cardioverter-defibrillators: A prospective multicenter study. European 7219 Jewel ICD investigators. Circulation. 1998;98:663-70.
20. Arya A, Haghjoo M, Emkanjoo Z, Dehghani MR, Sadr-Ameli MA. Does the rate of inappropriate therapy differ in implantable cardioverter-defibrillators from different manufacturers? J Interv Card Electrophysiol. 2006;17:59-63.